NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis $0.41 +0.08 (+25.42%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$0.40 -0.01 (-1.95%) As of 10/23/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Lucid Diagnostics Stock (NASDAQ:LUCD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lucid Diagnostics alerts:Sign Up Key Stats Today's Range$0.39▼$0.4550-Day Range$0.33▼$1.0152-Week Range$0.30▼$1.63Volume110.81 million shsAverage Volume4.77 million shsMarket Capitalization$83.53 millionP/E RatioN/ADividend YieldN/APrice Target$4.19Consensus RatingModerate Buy Company Overview Lucid Diagnostics Inc. (NASDAQ: LUCD) is a medical diagnostics company focused on improving the detection of esophageal disease. The company develops and commercializes diagnostic technologies intended to identify patients at elevated risk of esophageal cancer, particularly those with gastroesophageal reflux disease (GERD). Lucid’s principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with Barrett’s esophagus and esophageal cancer risk, and EsoCheck, a swallowable, balloon-based device designed to collect cells from the esophageal lining. The products are intended to support noninvasive or minimally invasive screening and help identify patients who may require further evaluation. Founded in 2018, Lucid Diagnostics is headquartered in New York and serves the U.S. market through healthcare providers, medical practices and other clinical channels. The company was co-founded by Lishan Aklog, M.D., who has served in leadership roles including chairman and chief executive officer. Lucid Diagnostics operates as a subsidiary of PAVmed Inc.AI Generated. May Contain Errors. Read More Lucid Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreLUCD MarketRank™: 2.136625956245 of 5 starsLucid Diagnostics scored higher than 43% of companies evaluated by MarketBeat, and ranked 620th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingLucid Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLucid Diagnostics has a consensus price target of $4.19, representing about 918.9% upside from its current price of $0.41.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 3 research reports in the past 90 days.Read more about Lucid Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.23) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lucid Diagnostics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.11% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 10.32, which indicates bearish sentiment.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 4.87%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.24 News SentimentLucid Diagnostics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows3 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lucid Diagnostics' insider trading history. Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUCD Stock News HeadlinesBTIG Research Reaffirms Buy Rating for Lucid Diagnostics (NASDAQ:LUCD)October 25 at 2:31 AM | americanbankingnews.comLucid Diagnostics Analyst Price TargetsOctober 23 at 10:44 PM | benzinga.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.October 25 at 1:00 AM | Profits Run (Ad)Lucid Shares Jump 40% Overnight On EsoGuard Medicare Payments, $15 Mln FinancingOctober 23 at 12:43 PM | rttnews.comLucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million FinancingOctober 22 at 4:20 PM | prnewswire.comLucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysSeptember 22, 2026 | prnewswire.comLucid Diagnostics Earnings Call Balances Progress and RiskAugust 21, 2026 | tipranks.comLucid Diagnostics (LUCD) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | finance.yahoo.comSee More Headlines LUCD Stock Analysis - Frequently Asked Questions How have LUCD shares performed this year? Lucid Diagnostics' stock was trading at $1.09 at the start of the year. Since then, LUCD shares have decreased by 62.3% and is now trading at $0.4110. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.00. The business earned $1.47 million during the quarter, compared to analyst estimates of $1.43 million. Read the conference call transcript. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an initial public offering (IPO) on Tuesday, October 12th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lucid Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include NVIDIA (NVDA), Tesla (TSLA), PAVmed (PAVM), Lucid Group (LCID), Advanced Micro Devices (AMD), Gevo (GEVO) and Marvell Technology (MRVL). Company Calendar Last Earnings8/12/2026Today10/25/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LUCD's financial health is in the Red zone, according to TradeSmith. LUCD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LUCD CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees82Year Founded1991Price Target and Rating Average Price Target for Lucid Diagnostics$4.19 High Price Target$9.25 Low Price Target$2.00 Potential Upside/Downside+918.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.01 million Net Margins-959.76% Pretax Margin-959.76% Return on EquityN/A Return on Assets-119.57% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.31 Sales & Book Value Annual Sales$5.45 million Price / Sales15.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.31) per share Price / Book-1.33Miscellaneous Outstanding Shares203,244,000Free Float189,220,000Market Cap$83.53 million OptionableNo Data Beta1.12 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:LUCD) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
